[1] Barlow SE,Dietz WH.Obesity evaluation and treatment:expert committee recommendations[J].Pediatrics,1998,102 (3):e29. [2] Noriyuki O,Akiko H,Koji O,et al.Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity[J].Science,2010,329 (5990):454-457. [3] Lagathu C.Dact1.A nutritionally regulated preadipocyte gene,controls adipogenesis by coordinating the wnt/2-catenin signaling network[J].Diabetes,2009,58 (3):609-619. [4] Schulte DM,Müller N,Neumann K,et al.Pro-Inflammatory wnt5a and Anti-Inflammatory sFRP5 are differentially regulated by nutritional factors in obese human subjects[J].Plos One,2012,7 (2):476-476. [5] 中国肥胖问题工作组.中国学龄儿童青少年超重、肥胖筛查体重指数值分类标准[J].中华流行病学杂志,2004,25(2):97-102. [6] 中华医学会儿科学分会内分泌遗传代谢学组,傅君芬,梁黎.中国儿童青少年代谢综合征定义和防治建议[J].中华儿科杂志,2012,50 (6):420-422. [7] 陈雪峰,梁黎,傅君芬,等.中国儿童青少年形体测量学参数调查[J].中华流行病学杂志,2012,54(2):33-34. [8] 米杰,王天有,孟玲慧,等.中国儿童青少年血压参照标准的研究制定[J].中国循证儿科杂志,2010,5(1):4-14. [9] Rourke JL,Dranse HJ,Sinal CJ.Towards an integrative approach to understanding the role of chemerin in human health and disease[J].Obesity Reviews,2013,14(3):245-262. [10] Minnie H,Mulders SM,Friis RR,et al.Expression and localization of secreted frizzled-related protein-4 in the rodent ovary:Evidence for selective up-regulation in luteinized granulosa cells[J].Endocrinology,2003,144(10):4597-4606. [11] Hasan A,Gunjan T,Jianmei L,et al.Fasting plasma leptin level is a surrogate measure of insulin sensitivity[J].Journal of Clinical Endocrinology & Metabolism,2010,95 (8):3836-3843. [12] Inoue M,Maehata E,Yano M,et al.Correlation between the adiponectin-leptin ratio and parameters of insulin resistance in patients with type 2 diabetes[J].Metabolism Clinical & Experimental,2005,54(3):281-286. [13] Salinas PC.Wnt signaling in the vertebrate central nervous system:from axon guidance to synaptic function[J].Cold Spring Harbor Perspectives in Biology,2012,4(2):441-441. [14] Camp JKV,Beckers S,Zegers D,et al.Common genetic variation in sFRP5 is associated with fat distribution in men[J].Endocrine,2014,46 (3):477-484. |